ORIC Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Net Income	-100.7	-89.12	-78.72	-73.7	-26.88	-21.36
Depreciation & Amortization	1.03	0.97	0.9	0.97	1.03	0.9
Share-Based Compensation	15.23	14.46	12.85	5.28	1.09	0.47
Other Operating Activities	-1.25	-1.45	5.42	22.19	1.23	-0.69
Operating Cash Flow	-85.69	-75.14	-59.54	-45.27	-23.53	-20.68
Capital Expenditures	-0.85	-2.08	-0.94	-0.67	-0.77	-0.53
Change in Investments	-42.55	-107.17	159.37	-215.29	0	0.02
Investing Cash Flow	-43.4	-109.25	158.44	-215.96	-0.77	-0.51
Share Issuance / Repurchase	85.89	25.62	50.99	271.75	0.13	0.08
Other Financing Activities	-0.23	-0.4	-1.85	-21.24	70.69	37.93
Financing Cash Flow	85.66	25.23	49.13	250.51	70.82	38.01
Net Cash Flow	-43.43	-159.17	148.03	-10.71	46.52	16.82
Free Cash Flow	-86.54	-77.22	-60.48	-45.94	-24.3	-21.21
Free Cash Flow Per Share	-1.68	-1.95	-1.59	-2.09	-12.79	-12.23

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).